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Background: The abuse of antimicrobical
drugs has increased the resistance of
microorganisms to treatments, thus to make urinary tract
infections (UTIs) more difficult to eradicate. Among natural
substances used to prevent UTI, literature has provided
 preliminary data of the beneficial effects of D-mannose,  
N-acetylcysteine, and Morinda citrifolia fruit extract, due to
their complementary mechanism of action which contributes
respectively to limit bacteria adhesion to the urothelium, to
destroy bacterial pathogenic biofilm, and to the anti-inflam-
matory and analgesic activity. The purpose of this study was
to compare the administration of an association of 
D-mannose, N-acetylcysteine (NAC) and Morinda citrifolia
extract versus antibiotic therapy in the prophylaxis of UTIs
potentially associated with urological mini-invasive
 diagnostics procedures, in clinical model of the urodynamic
investigation.
Methods: 80 patients eligible for urodynamic examination, 
42 men and 38 women, have been prospectively enrolled in
the study and randomised in two groups (A and B) of 40
 individuals. Patients of group A followed antibiotic therapy
with Prulifloxacine, by mouth 400 mg/day for 5 days, while
patients of the group B followed the association of mannose
and NAC therapy, two vials/day for 7 days. Ten days after 
the urodynamic study, the patients were submitted to urine
examination and urine culture. 
Results: The follow up assessment didn't show statistical
 significant difference between the two groups regarding the
incidence of UTI. 
Conclusions: The association of mannose and NAC therapy
resulted similar to the antibiotic therapy in preventing UTIs 
in patients submitted to urodynamic examination. 
This result leads to consider the possible use of these
nutraceutical agents as a good alternative in the prophylaxis
of the UTI afterwards urological procedures in urodynamics. 
KEY WORDS: Urinary Tract Infection (UTI); D-mannose - 
N-acetylcysteine (NAC); Urodynamic; Biofilm.
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INTRODUCTION
Urinary tract infections (UTIs) are defined as the presence
and the proliferation of bacteria which are pathogens in
one or more parts of the urinary tract with subsequent
invasion of tissue and the onset of symptoms. UTIs repre-
sent a great problem for the public health systems,
because they are responsible for high morbility and are
also one of the main causes of antibiotic prescriptions
associated to an increased resistance to them (1). 
In Europe UTIs represent the second cause of bacterial
infection, after the respiratory, and are the most frequent
form of nosocomial infections, associated mostly to the
bladder catheterism (2, 3). Furthermore, the high volume
of antibiotics used to face UTIs determines high costs for
the sanitary systems and their abuse has significantly con-
tributed to the development of resistance mechanisms of
the germs to these drugs (4). Females are usually more
exposed to this pathologic condition due to anatomical
factors. However, after the age of 50, the risk of UTI
increases also for men because of obstructive problems
due to the benign prostatic hypertrophy (Table 1). 
Some other factors may contribute to increase the risk of
developing UTI, and they should not be underestimated,
such as intrauterine contraceptives (spiral), pregnancy
(because it causes urinary stasis), menopausal status,
anatomical and endocrine disrupters, constipation, wrong
behavioural habits, various types of urinary catheterisms
(ureteral stent, nephrostomy, intermittent or indwelling
bladder catheterization). The Annual Epidemiological report
of the European Centre for Disease Prevention and Control
(ECDC) published in April 2015, reported that pathogen-
ic agent which is responsible of most UTIs (about 70%) is
Escherichia coli, a bacteria of faecal origin which belongs to
the gram-negative (5). E. coli is an emerging problem also
regarding community acquired UTI either in pediatric
population either in the adult and elderly subjects (4).
Particularly, subjects with severe chronic urinary dysfunc-
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tions secondary to neuropathies and people recovered in
intensive care units are exposed to UTIs (6, 7). 
For these reasons, a better understanding of mechanisms
which induce the germs’ resistance to antibiotics is need-
ed, such as improvement of the strategies to prevent
infections and their recurrences, with the aim to limit use
of antibiosis in the clinical practice. 
In the urinary tract, the interaction between pathogen
bacteria and the epithelium is mediated by various fac-
tors located on the bacteria cell or secreted by the same.
In fact, adhesion of bacteria is a complex process,
depending on the presence of certain fimbrial/pili struc-
tures that allow a specific interaction of the microbe with
certain host cell receptors (8). These structures are rep-
resented by proteins, called adhesins, that allow the spe-
cific and selective bacterial adhesion. Specifically, two
different types of pili are distinguished: 1) mannose -
sensitive, pili or fimbria type I; 2) mannose - resistant,
pili or fimbria type II.
The type I are the main responsible factor for the colo-
nization and invasion of the lower urinary tract due to
the adhesion at urothelium cells level (8). However,
another feature of the pathogen bacteria is the ability to
produce, under favourable conditions, a large quantity of
a particular capsular material: the biofilm (9, 10).
Pathogenic biofilms represent the still neglected etiology
of recurrences. Biofilms are polimicrobial structured
communities, composed by 15% of bacteria and/or fungi
and 85% of a self-produced mucopolysaccharides poly-
meric matrix. On biological surface, biofilms can be
intra- or extracellular, in the bladder or on mucous sur-
face respectively, but they can also adhere to an inert
structure, such as catether or other medical device.
Pathogens live in a quiescent state in the deep layers of
biofilm as “persister cells”, phenotypically resistant to
antibiotics and host defences and ready to re-attack the
host. Biofilm has an important role in UTIs pathogenesis,
especially when intracellular, established inside bladder
cells, because it doesn’t allow to pharmacological treat-
ments and to the autoimmune system to reach bacteria
efficiently. Furthermore, biofilm have a complex and
ingenious architecture that mimics a primitive circulato-
ry system, with particular structures called "water chan-
nels" and "pore", allow both the distribution of nutrient,
signalling molecule, for the removal of toxic substances
too (10). It also allows the transition of genes, thanks to
the physical proximity of bacterial cells, contributing to
resistant infections and drugs- resistance (11). 
Particularly considering the risk to induce drugs resist-
ance by germs, the possible side effects, such as intestin-
al dysbiosis, the use of antibiotics should be very careful.
Aim of this research is to find an alternative natural
approach instead of antibiotics prophylaxis to prevent
UTIs, such as in mini-invasive diagnostic urodynamics
procedures. In fact, a large use of antibiotics is applied to
prevent infections, especially in men, potentially related to
various diagnostic invasive urological examinations.
Considering the pathophysiologic mechanisms that most-
ly contribute to the bacteria adhesion, to prevent the
attachment and pathologic growth of bacteria and to pro-
mote the degradation of biofilm, must be considered as
one of the main strategies to reduce the risk of UTIs. 
An alternative to the antibiotic prophylaxis, in the preven-
tion of UTIs which can arise after urological procedures,
could be the use of natural substances, especially when
the microbial load is still low. One of these substances is
D-mannose, an inert monosaccharide which is physiologi-
cally present in the human body (12-14). After assump-
tion, D-mannose is sparely metabolized, and mostly
removed through the urine. The mechanism of action is
represented by the inhibition of bacterial adhesion to the
urothelium, interfering with fimbrial adhesins type I -
Mannose - sensitive. 
D-mannose plays an important role also in other func-
tions such as the ability to regenerate glycosaminogly-
cans (GAGs) of bladder and mucosal surface, after
injury, and to detach bacteria already linked at the
urothelium (12-14). Its beneficial effects in reducing UTI
and complementary and integrative therapy for lower
urinary tract inflammatory diseases have been shown by
various studies (15-17). However, D-mannose is ineffec-
tive against the pathogens inside biofilm thus to induce
the need of further action to better prevent the persist-
ence and recurrence of UTI, and the bacterial resistance. 
Some evidence has already been provided about the abil-
ity of N-acetylcysteine on reducing bacterial biofilm either
in vitro and in vivo studies (18, 19). These investigations
showed a clinical benefit due to an high ability to dis-
Table 1. 
Risk factors and prevalence of UTIs according to the age and sex.
Women Men
Age Prevalence (%) Risk factors Prevalence (%) Risk factors
< 1 1 Functional or anatomic alterations of the urinary tract; 1 Functional or anatomic alterations of the urinary tract;
Incomplete immune system Incomplete immune system
1-5 4-5 Vesicoureteral reflux; congenital alterations 0.5 Congenital alterations
6-15 4-5 Vesiureteral reflux 0.5 No
16-35 20 Sexual relations; Diaphragm/spiral and spermicide; 0.5 Sexual relations
Pregnancy
36-65 35 Estrogens deficit (post-menopausal); 20 Vesicoureteral reflux;
gynaecological surgery; neurological disorders; benign prostatic hyperplasia; stenosis;
vesicoureteral reflux; vaginal prolapse; neurological disorders; surgery;
instrumentations; dismetabolic disease; lithiasis instrumentations; dismetabolic disease; lithiasis
> 65 30 Idem + incontinence, bladder catheterism; 35 Idem + incontinence, bladder catheterism;
antimicrobical therapy antimicrobical therapy
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solve the ripe biofilm matrix. Therefore, it has already
been reported that N-acetylcysteine could be useful in the
treatment of UTI, also caused by E. coli, due to its
inhibitory effect on both bacterial growth and biofilm
formation (20).
In recent years, the growing interest in phytotherapic
remedies has focused a particular interest also to Morinda
citrifolia fruit, a native plant of South - East Asia, Polynesia
and Hawaii. The demonstrated range of therapeutic
effects of Morinda citrifolia fruit is attributable to the rich-
ness of its chemical components: Xeronine, Proxeronine,
Scopoletin, Octoanoic acid, potassium, vitamin C, terpenoids,
alkaloids, anthraquinones, linoleic acid, Alizarin, amino
acids, Acubine, L-asperuloside, caprylic acid, ursolic acid,
rutin, carotene, vitamin A (21). The dry fruit extract is
commonly used in various nutritional supplements
products for its antibacterial, anti-inflammatory, anal-
gesic and immunomodulatory activity, suggesting a great
role also in recurrent UTIs prevention.
For all the overmentioned considerations, it appeared of
interest to design a study to evaluate the efficacy of a
combination of D-mannose, N-acetylcysteine and Morinda
citrifolia extract on UTIs after urodynamic procedures. 
Aim of this clinical study was to compare assumption
of a phytoterapic product composed by D-mannose, 
N-acetylcysteine and Morinda citrifolia extract (registered
as Ausilium NAC® by Deakos s.r.l. Corso Nazionale, 169 -
La Spezia), versus the antibiotic prophylaxis with fluo-
rochinolones, in preventing UTIs potentially related to
mini-invasive urological diagnostic procedures. To
achieve this goal, the urodynamic examination repre-
sented the experimental clinical model. 
MATERIALS AND METHODS
The clinical study has been conducted at the University of
Rome, La Sapienza, Unit of Urology, ICOT Hospital, Latina.
From February to September 2015, 80 patients have
been subjected to the urodynamic examination. Patients
have been chosen random in a cohort study including 42
men and 38 women. At the preliminary urologic consul-
tation, all patients were submitted to history, physical
examination including digital rectal examination in men
and vaginal exploration in women. The day for the uro-
dynamic investigation was planned and all the subjects
were invited to present urine examination and urine cul-
ture 7 days before the test. Patients with pathological
findings at urine examination (presence of nitrites and
pathological number of leukocytes in the urine sedi-
ment) and/or with positive urine culture suggestive for
UTI (defined by > 105 colony-forming units/Ml) were
invited to assume antibiotics basing on antibiogram and
were excluded from this protocol. All the other patients
with negative urine examination and negative urine cul-
ture were considered and accepted to be screened for the
study, after they have signed an informed consent.
Inclusion criteria were considered: legal age (18 years in
Italy) and ability to understand and sign the informed
consent. 
Exclusion criteria were represented by: history of recent
hematuria (within 3 months), presence of indwelling
catheter or nephrostomy or suprapubic catheter or
ureteral stent, recent urological, gynaecological or pelvic
surgery (within 3 months), neoplastic disease, evidence
or suspicious of fistula, diagnosis of interstitial cystitis,
pathological findings at physical examination (e.g., digi-
tal rectal exploration suspicious for prostate cancer or
suggestive for prostatitis). All patients satisfying inclu-
sion criteria were then enrolled. Therefore, the 80
patients considered for the protocol came from a prelim-
inary population of 134 individuals attending our outpa-
tient office. Following those criteria, a randomized pro-
cedure was used for the random allocation of the
enrolled patients into two groups of 40 in equal propor-
tions to ensure a uniform allocation ratio (1:1). A specific
protocol has been developed for each group:
Group A: traditional treatment with antibiotics
Prulifloxacine by mouth, 400 mg/day, for 5 days starting
from the day before the procedure. Prulifloxacine is the
antibiotic suggested by the service for the prevention and
treatment of the infective diseases of the hospital; thus it
represents the recommended antibiotic for urological prac-
tice in our institution. 
Group B: oral administration of two vials/day of Ausilium
NAC® for 7 days starting from the day of the examina-
tion. Each vial contain D-mannose 500 mg, N-acetylcys-
teine 100 mg and Morinda citrifolia fruit extract 300 mg,
an anti-inflammatory, immunostimulant and analgesic
phytoteraphic remedy. 
After 10 days from urodynamic test, a second laboratory
assessment based on urine examination and urine cul-
ture was performed in all patients. Results were observed
and submitted to statistical analysis, which was per-
formed using the S-PSS 20.0 software. At beginning, a
careful analysis was conduct to evaluated the statistical
homogeneity among the two groups (either pluri-
floxacine, or Ausilium NAC®) according to the demo-
graphic data and comorbidities. Then, patients were
compared according to their group allocation and analy-
sis of variance was used to find the significance of study
parameters among the groups of patients. Fisher’s exact
test, Mann-Whitney, and 95% confidence intervals were
used as appropriate. Two-tailed p value of less than 0.05
was considered as statistically significant. The local
Ethical Committee, as prescribed by law, was informed
of this observational investigation before starting the
protocol. Schematic overview of experimental design is
represented in Figure 1.
RESULTS
The results obtained from the anamnestic assessments
between the two groups did not show significant differ-
ence in relation to the age, sex, body mass index,
menopausal status, co-morbidities and pharmacotherapy
(p value > 0.05). The population enrolled in the study
was stratified according to the age, benign prostatic
hyperplasia (BPH), menopausal status, different birthing
modalities, hypertension/heart diseases, diabetes, dys-
thyroidism, gynaecological and urological surgery or
other pathologies, called “Other” (such as osteoporosis,
dyslipidaemia, depressive illness, etc.) as indicated in
Table 2. During the treatment, 5 patients spontaneously
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abandoned the study due to scarce interest in continuing
the protocol: 2 of them (both men) belonged to the
Group A and 3 (1 man and 2 women) belonged to the
Group B. Patients who left the study have been excluded
from the final evaluation. At the end of the study, 75
patients have been evaluated: 38 belonging to the group
A and 37 belonging to the group B. They have been
divided in other sub-groups according to sex: therefore,
21/38 patients (55%) of
group A and 18/37 patients
(49%) of group B were men,
while 17/38 patients (45%)
of group A and 19/37
patients (51%) of group B
were women. None patient
reported side effects in both
treatment groups. Schematic
overview of experimental
design and results obtained
are represented in Figure 1.
Obtained data denotes the
same UTIs incidence in the
two observed groups: 3/38
(7.89%) of the group A and
2/37 (5.4%) of the group
B developed UTIs (p value =
0.671) (Table 3). 
Considering the laboratory
examinations performed at the
follow-up visit, the results
didn't show significant differ-
ences between the group A
and B in terms of incidence
of UTIs.
All the patients with UTIs
were symptomatic; they were
Prulifloxacine Ausilium NAC
Men Women Tot Men Women Tot
Patients n = 21 n = 17 n = 38 n = 18                  n = 19            n = 37
Average age (± 95%) 65 (± 1.62) 56 (± 1.39) 65.4 (± 1.03) 64 (± 1.45)    54.42 (± 1.88)     65.4 (± 1.09)
Diabets 3 1 4 4 1 5
Menopausal status / 12 12 / 11 11
B.P.H.* 15 / 15 12 / 12
Hypertension/heart disease 2 2 4 1 2 3
Dysthyroidism 1 1 2 / 1 1
Natural childbirth / 3 3 / 4 4
Urological surgery 2 / 2 2 / 2
Uro-gynaecological surgery / 3 3 / 5 5
Other / 4 4 / 2 2
* Benign Prostatic Hyperplasia.
Figure 1. 
Schematic overview of experimental design and results obtained in the study.
Table 3. 
Percentage of UTIs occurred and germ isolated in the patients from group A, group B and sub-groups according to the sex.
Table 2. 
Clinical and demographic characteristics of the two experimental groups performed. 
Patients Group A Group B
analyzed Prulifloxacine D-mannose and N-acetylcysteine
Sex Men Women Tot Men Women Tot
N° patients 75 21 17 38 18 19 37
% UTIs 9.5% 5,8%                7.89% 5.5%                5.2%                5.4%
Germ isolated Escherichia coli 100% Escherichia coli 100%
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treated with antibiotics basing on antibiogram, followed
by further laboratory check after 15 days to ensure that
UTI was cured. 
The group A and B have been divided in other two sub-
groups in relation to the sex. Only 2/21 (9.5%) male
patients and 1/17 (5.8%) female patients of the group A
and 1/18 (5.5%) male patients and 1/19 (5.2%) female
patients of the group B developed UTI after urodynamic
procedures (p value = 0.946). 
The results of this further division did not show particu-
lar predispositions to UTIs depending on the sex, antibi-
otics or nutraceuticals in urodynamic. 
DISCUSSION
The results of this study show that there was no signifi-
cant difference regarding the incidence of UTIs between
patients undergone treatment with fluorochinolones and
those who assumed Ausilium NAC®. 
The phytotherapic product combines D-mannose, able to
reduce bacterial adhesion, N-acetylcysteine, a mucolitic
molecule useful to destroy bacterial biofilms and
Morinda citrifolia extract, with anti-inflammatory,
immune stimulating and analgesic properties, in UTIs
after urodynamics procedures. Therefore, assumption of
Ausilium NAC®, two vials/day for one week provided the
same protective effect in preventing UTIs respect to the
prophylaxis with fluorochinolone Prulifloxacine. The two
compared cohorts were substantially similar regarding
comorbidities and clinical features, therefore this result
has been not conditioned by clinical and demographical
differences between the populations and it has to be
specifically related to the action of treatments used. In
case of invasive diagnostic urological procedure, which
potentially carry the risk to induce UTIs, a very careful
protocol is essential, such as sterility of instruments or
correct prophylaxis post-intervention. As an additional
strategy to reduce the risk of UTIs, instead of using
antibiotics it should be preferable to use natural sub-
stances, basing on the evidence that these agents could
provide the same protection especially when microbial
load is still very low. 
In vitro studies and preliminary clinical experiences
demonstrated that D-mannose and N-acetylcysteine can
provide a favourable effect in preventing UTIs (12, 15-
20). The present study shows that D-mannose, N-acetyl-
cysteine in association with Morinda citrifolia fruit extract
in the formulation of Ausilium NAC®, like plurifloxacine,
may provide a favourable effect in preventing UTI in case
of mini-invasive diagnostic procedures which require
bladder catheterism. An important advantage of
nutraceutical agents is that a natural mechanism to pre-
vent infections can avoid an unnecessary use of antibi-
otics, limiting the risk to develop germ resistance.
Furthermore, even if it did not happen in our study, usu-
ally antibiotics are more responsible for dysbiosis and
side effects if compared with natural substances. As a
further consideration, patients accepted with pleasure to
assume a nutraceutical agents rather than antibiotic pro-
phylaxis to prevent UTIs. 
The results obtained suggest to better explore, on larger
case series, the advantage of this particular association of
nutraceuticals, whose action mechanisms are of particu-
larly suitable interest in UTIs prevention. 
The synergy between D-mannose, N-acetylcysteine, and
Morinda citrifolia fruit extract, has suggested a great role
in recurrent UTIs prevention (15-21). 
A larger experience is needed, also in different type of
populations, to amplify the outcomes shown in the pres-
ent study. In fact, the limit of this study is represented by
the single centre experience and the relatively limited
number of subjects enrolled. However, the stratification
of patients and the prospective design can partially bal-
ance these limits. Another criticism could be represented
by the absence of a “non-treatment” group, but this was
not allowed by the Local Ethical Committee. As a further
consideration, it has to be underlined that, as various
type of infections, also the risk of UTI may be strongly
reduced by some other natural and non invasive preven-
tion strategies. Behavioural aspects, reduction of comor-
bidities and attention to precipitating factors, are the
most important. As a favourable consequence, a better
management of antibiotics could limit the development
of germ resistance which is becoming a serious health
problem, particularly in hospitalized patients (8). 
In fact, in the last years, many Authors reported the
increased of UTI secondary to germs resistant to conven-
tional antibiotic treatment (21). It is a common experi-
ence in real life management to face UTI sustained by
germs which show multiple resistance, and one of the
main factors that has led to multiple resistance is the
indiscriminate use of antibiotics. Those circumstances
require difficult strategies of treatment. Sometimes it is
necessary the help of experts in contagious disease, a large
dose of medicines and also hospitalization. Furthermore,
in the last years considering the large availability of effica-
cious antibiotics, clinicians have made an excessive use
and at the same time the research for new molecules has
been decreased; therefore new classes of drugs suitable for
the treatment of infections caused by multidrug-resistant
germs are not currently available. For these reasons
antibiosis prophylaxis must be restricted and replaced
with alternative treatment whenever possible. 
CONCLUSIONS
This study proved that Ausilium NAC® is as efficient as the
plurifloxacin in order to prevent UTIs potentially associat-
ed with urodynamic examination. This result should
induce to consider that the assumption of nutraceutical
substances without antibiotic effect can reduce the risk of
UTIs, for less invasive urological procedures. The limited
use of antibiotics in selected cases will contribute to
reduce the development of antibacterial agents resistance.
Further studies are requested to support the encouraging
results of this experience, focusing the attention on a more
careful use of antibiotics for UTIs prevention related to
diagnostic procedures. 
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